Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) EBIT Margin (2019 - 2025)

Silo Pharma's EBIT Margin history spans 7 years, with the latest figure at 6388.16% for Q3 2025.

  • For Q3 2025, EBIT Margin fell 78453.0% year-over-year to 6388.16%; the TTM value through Sep 2025 reached 1511.78%, up 411368.0%, while the annual FY2024 figure was 677.13%, 467028.0% up from the prior year.
  • EBIT Margin for Q3 2025 was 6388.16% at Silo Pharma, up from 6926.77% in the prior quarter.
  • Across five years, EBIT Margin topped out at 574643.9% in Q4 2021 and bottomed at 9192.04% in Q4 2022.
  • The 5-year median for EBIT Margin is 5072.45% (2022), against an average of 33866.86%.
  • The largest annual shift saw EBIT Margin surged 57731733bps in 2021 before it plummeted -58383595bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 574643.9% in 2021, then plummeted by -102bps to 9192.04% in 2022, then increased by 30bps to 6455.81% in 2023, then soared by 307bps to 13336.93% in 2024, then tumbled by -148bps to 6388.16% in 2025.
  • Per Business Quant, the three most recent readings for SILO's EBIT Margin are 6388.16% (Q3 2025), 6926.77% (Q2 2025), and 6069.68% (Q1 2025).